Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
FiercePharma13h
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
BioPharma Dive15h
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
The Pharma Letter3h
FDA nod for Vertex’ non-opioid pain drug Journavx
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
BioSpace15h
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
India Today on MSN10h
Vertex: New non-opioid painkiller Journavx approved by FDA
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...